Skip to content

Study on the Effects of Saccharomyces Boulardii Probiotics on Adolescent Depression: A Multicenter, Randomized, Double-Blind Controlled Trial

Study on the Effects of Yeast Probiotics on Adolescent Mental Health

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400091133
Enrollment
Unknown
Registered
2024-10-21
Start date
2024-10-25
Completion date
Unknown
Last updated
2024-10-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Major Depressive Disorder

Interventions

Intervention group:Saccharomyces boulardii probiotics
participants in the intervention group consumed one sachet of Saccharomyces boulardii powder every morning at breakfast, with a dosage of 5 x 10^9 colony-forming units (CFU).
Control group:Placebo
participants in the control group received a placebo sachet with an identical appearance, containing only maltodextrin and no Saccharomyces boulardii strain. The placebo was indistinguishable from Sac

Sponsors

Wuhan university
Lead Sponsor

Eligibility

Sex/Gender
All
Age
13 Years to 18 Years

Inclusion criteria

Inclusion criteria: 1. Age between 13 and 18 years old, voluntarily participating and completing the study with informed consent from their guardian. 2. Participants meet the diagnostic criteria for depression as per the Chinese Classification of Mental Disorders, 3rd edition (CCMD-3). 3. Normal language and hearing abilities. 4. Participants do not consume probiotic-rich fermented foods during the study. 5. All participants are on a stable dose of the same antidepressant medication for at least 6 weeks prior to the study, and are required to maintain this regimen throughout the study.

Exclusion criteria

Exclusion criteria: 1. Diagnosis of bipolar disorder. 2. Plans for hospitalization or surgery within 3 months. 3. History of allergic reactions within 3 months prior to the trial. 4. Allergy to any components of the supplement (Saccharomyces boulardii, maltodextrin). 5. Body mass index (BMI) over 30. 6. Use of systemic antibiotics or antifungal agents within 3 months prior to the trial. 7. Intake of other probiotics within 3 months prior to the trial. 8. Vegetarian diet. Additionally, participants who experience serious adverse reactions will be withdrawn from the trial.

Design outcomes

Primary

MeasureTime frame
Depression score;

Secondary

MeasureTime frame
anxiety score;Overall clinical status;Salivary cortisol;Gut microbiota;Short-chain fatty acids (SCFAs);

Countries

China

Contacts

Public ContactRui Li

School of Nursing, Wuhan University

rli@whu.edu.cn+86 177 0275 0208

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026